Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma - Salles, Gilles; Długosz-Danecka, Monika; Ghesquières, Hervé; Jurczak, Wojciech (Expert opinion on biological therapy, 2021)
Keywords: CD19; diffuse large B-cell lymphoma/DLBCL; immunotherapy; lenalidomide; MOR208; non-Hodgkin's lymphoma/NHL; tafasitamab; diffuse large B-cell lymphoma/DLBCL; CD19; immunotherapy; tafasitamab; lenalidomide; MOR208; non-Hodgkin’s lymphoma/NHL